China Resources-affiliated maker of hospital generic and injectable drugs across a broad range of therapeutic areas.
China Resources-affiliated maker of hospital generic and injectable drugs across a broad range of therapeutic areas.
Sells drugs through distributors to public hospitals, where prices for many generics are set by national volume-based procurement auctions, so winning a contract trades lower prices for guaranteed volume. China Resources, the state-owned conglomerate, controls it and helps with distribution.
In one line: A Chinese hospital-generics Hospira.
Moat: none (scale, distribution). Broad generic portfolio and China Resources group distribution support, but limited pricing power.
Headquarters: Beijing, China · Employees: 13,184
Size China Resources Double-Crane Pharmaceutical (600062.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $2.35B, the 1020th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.08 on 18 Nov 2026.
Performance Over six months the shares fell 14.2%, against -0.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 1.5% over the last twelve months (peer median +10.2%); the operating margin is 12.6% (peer median 16.4%).
Valuation It trades at 9.3× forward earnings against a peer median of 17.6× (2nd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.8B | CN¥10.9B | CN¥11.1B | CN¥11.2B | CN¥9.57B |
| Revenue growth | — | -2% | -1% | +17% | — |
| Gross profit | CN¥6.46B | CN¥5.97B | CN¥6.08B | CN¥6.11B | CN¥4.97B |
| EBITDA | n/a | CN¥2.47B | CN¥2.37B | CN¥2.39B | CN¥1.80B |
| Net income | CN¥1.57B | CN¥1.65B | CN¥1.63B | CN¥1.67B | CN¥1.18B |
| Free cash flow | CN¥985M | CN¥1.00B | CN¥1.21B | CN¥1.33B | CN¥984M |
| Capital expenditure | CN¥557M | CN¥620M | CN¥637M | CN¥614M | CN¥527M |
| Total debt | CN¥2.14B | CN¥1.27B | CN¥1.32B | CN¥467M | CN¥440M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Resources Double-Crane Pharmaceutical 600062.SS | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| Sichuan Kelun Pharmaceutical 002422.SZ | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600062.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.3% | -1.2% | 5th lowest of 21 |
| 6-month return | -14.2% | -0.1% | 6th lowest of 21 |
| Distance from 52-week high | -23.7% | -22.6% | 10th lowest of 21 |
| Revenue growth (TTM) | -1.5% | +10.2% | 6th lowest of 21 |
| Operating margin | 12.6% | 16.4% | 8th lowest of 21 |
| Forward P/E | 9.3× | 17.6× | 2nd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -9.1% | 2.1% | 2nd least demanding of 20 |
| Growth delivered (Del g) | +5.3% | +10.4% | 8th lowest of 20 |
| Hurdle (Req g minus delivered) | -14.4 pp | -8.0 pp | 5th least demanding of 20 |
| ROIC minus cost of capital | +5.4 pp | +2.7 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% | +5.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% | +11.6% |
| By-health 300146.SZ | China | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% | +0.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% | +4.4% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $2.97B | -7% | -4% | -13% | n/a | 5.0% | +1.0% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.00B | +11% | -14% | 9% | 91.7× | 33.8% | +5.9% |
| Bausch Health Companies BHC.TO | Canada | $3.27B | +66% | +10% | 27% | 2.0× | -14.8% | +5.9% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $3.83B | -7% | +32% | 21% | 17.5× | -3.9% | -2.2% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Dong-E-E-Jiao 000423.SZ | China | $4.99B | +1% | +8% | 29% | 17.8× | -3.7% | +14.5% |